Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)
brief summary
The objectives of this study are: * To evaluate the safety of EscharEx and its placebo Gel Vehicle compared to non-surgical standard of care (NSSOC) * To assess the efficacy of EscharEx (EX-03 5% formulation) compared to placebo control and compared to NSSOC.
detailed description
45 eligible adult participants with VLU (with a surface area between 2 cm2 and 40 cm2 , and wound age between 4 weeks and 18 months), will be randomized. The participants will be treated with IMP (either EX-03 5% or placebo) in a double blinded manner or with NSSOC in unblinded manner.
Total duration of the study is up to 17 weeks:
Screening period (2 visits, 7 days apart),
Daily Visits Period (debridement with IMP/NSSOC): up to 8 daily site visits, (or less if a complete debridement occurred before 8 visits) within 14 days.
Weekly Visits Period (Wound management): the weekly period will include up to 13 visits in 12 weeks + optional wound closure confirmation (up to 2 weeks). Wound will be managed in a standardized manner.
official title
A Multicenter, Prospective, Randomized, Placebo and Non-Surgical Standard of Care (NSSOC) Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to NSSOC in Participants With Venous Leg Ulcers (VLU)